Mesothelioma.com Resources for Patients and their Families

Serum Biomarkers in Diagnosis of Mesothelioma

Brief Summary

In this study, the investigators analyzed the efficiencies of hyaluronan, osteopontin, C-ERC/mesothelin, N-ERC/mesothelin and syndecan-1 serum levels, both individually and in combination, in distinguishing malignant pleural mesothelioma patients from patients with metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy.

Tracking Information
First Received DateJanuary 6, 2014
Last Changed DateJanuary 6, 2014
Start DateJanuary 2004
Actual Primary Completion DateDecember 2010
Primary Outcome Measures

Serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin and syndecan -1 level in the patients with mesothelioma, metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy. [Time Frame: From January 2004 to December 2010]

Descriptive Information
PhaseN/A
Study TypeObservational
Condition
  • Mesothelioma
Intervention
  • Biological: Mesothelin, hyaluronan, osteopontin, syndecan-1
Study Arms / Comparison Groups0 / 1
Detailed Description

In the year 2002, a database for the pleural diseases was constructed to be prospectively filled in the department. The findings, outcome features and characteristics of follow-up for all cases with pleural diseases have been recorded in this database. The patient data, including epidemiological characteristics, smoking status, history of other diseases and co-morbid conditions, previous asbestos exposure, medications and additional physical and radiological examination findings, including computed tomography scans, both serum and pleural fluid laboratory investigational data and indications of invasive procedures, were recorded in the database mentioned above. The methods employed in the diagnosis of patients; any complications; characteristics such as the stages of diseases, treatments, and course of treatments; and results were also recorded in the database. From the date of the first database establishment, a "tissue, blood, serum, and fluid specimen bank" was constructed; tissue, blood, serum and pleural fluid samples of patients, which had been taken at the beginning of diagnosis process, were stored in this bank at -80°C. The blood, serum, and pleural fluid samples of patients were stored during the diagnosis process, and if conducted, pleural tissue samples taken during invasive procedures were also stocked.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment230
GenderAll
Ages18 Years - 85 Years
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Patients with a definite pleural diseases

- Age more than 18 year-old, less than 85 year-old.

- Willingness to participate in the study.

Exclusion Criteria:

- Patients with undiagnosed pleural diseases.

- Age less than 18 year-old or more than 85 year-old.

Administrative Information
NCTIDNCT02029105
Responsible Party,
SponsorEskisehir Osmangazi University
Verification DateJanuary 2014
Mesothelioma Doctors by State
  • Trust Funds Set Aside
  • VA Benefits Available
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Baylor Mesothelioma Doctor Has High Hopes for Preoperative Immunotherapy

Health Insurance for Cancer Treatment: What to Know

Living with Mesothelioma: Claire Cowley Shares Her Husband’s Journey

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: